Compare RRX & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RRX | CYTK |
|---|---|---|
| Founded | 1955 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 7.6B |
| IPO Year | 1994 | 2004 |
| Metric | RRX | CYTK |
|---|---|---|
| Price | $209.28 | $66.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | ★ $209.70 | $89.26 |
| AVG Volume (30 Days) | 941.2K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | ★ 42.86 | N/A |
| EPS | ★ 4.20 | N/A |
| Revenue | ★ $3,257,100,000.00 | $13,368,000.00 |
| Revenue This Year | $4.15 | $6.88 |
| Revenue Next Year | $12.25 | $308.26 |
| P/E Ratio | $49.58 | ★ N/A |
| Revenue Growth | ★ 5.21 | N/A |
| 52 Week Low | $94.42 | $29.31 |
| 52 Week High | $229.30 | $70.98 |
| Indicator | RRX | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 59.02 |
| Support Level | $136.55 | $59.12 |
| Resistance Level | $227.65 | $69.48 |
| Average True Range (ATR) | 8.13 | 2.30 |
| MACD | 3.16 | 0.31 |
| Stochastic Oscillator | 97.89 | 78.72 |
Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors, electronic controls, air-moving products, and specialty electrical components and systems, serving customers around the world. The three operating segments include Automation & Motion Control (AMC) segment; Industrial Powertrain Solutions (IPS) segment, which derives maximum revenue; and Power Efficiency Solutions (PES) segment. Geographically, the company operates in North America, Europe, Asia, and Rest of the world, of which it derives maximum revenue from North America.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.